CAR T-Cell Cancer Therapy to Be Approved in Japan
Newsfrom JapanSociety Lifestyle Politics
Tokyo, Feb. 20 (Jiji Press)--An expert panel of Japan's health ministry on Wednesday expressed its approval of the production and sales of a chimeric antigen receptor (CAR) T-cell cancer therapy.
The health minister is expected to give the final approval in the near future. This will be followed by the process to fix its price under the country's public health insurance system.
The CAR T-cell therapy is likely to join the list of drugs and treatments covered by the system as early as May, according to informed sources.
In the therapy, T-cells, a type of immune system cells, are taken out of a cancer patient and put back in after being genetically modified to attack cancer cells.
The Japanese government approval will be given to the Kymriah therapy developed by Swiss pharmaceutical giant Novartis.
[Copyright The Jiji Press, Ltd.]